Femasys Inc. products

FemBloc features our proprietary delivery platform, which places balloon technology close to the opening of both fallopian tubes. This in-office approach is designed to eliminate the risks of incisions, anesthesia, and hormones. As a nonsurgical procedure that is implant free, FemBloc delivers a biopolymer that is expected to expel within 3 months. Confirmation of procedure success can be achieved after 90 days, which would provide women with a certainty no other option can achieve.

FemVue is the first FDA-cleared product that creates natural saline and air contrast and enables safe, reliable, and real time evaluation of the fallopian tubes with ultrasound. When performed with a uterine cavity assessment, a more comprehensive exam can be achieved from the comfort of the GYN’s office.

FemCerv, an FDA-cleared endocervical sampler, is the first to be designed for capture of a complete and uncontaminated sample in a relatively pain-free procedure. FemCerv features an expandable collection chamber that is exposed during sampling and closed during removal for containment of cervical cells and tissue.

FemCath, an FDA-cleared intrauterine catheter, is the first to allow for selective evaluation of a fallopian tube with contrast. FemCath features our proprietary delivery platform, which places balloon technology close to the opening of a selected fallopian tube for directed delivery.

FemaSeed is a novel solution in development for insemination that can be performed as a first-line therapeutic option. It would be the first and only directed approach designed to be more affordable than assisted reproduction, such as in vitro fertilization (IVF). FemaSeed features our proprietary delivery platform, which places balloon technology close to the opening of a selected fallopian tube. Unlike any other infertility approach, it is designed to deliver sperm directly to the ovulating side, where conception occurs.